Robin Shane Readnour sold $6,675 of ANTX
director at AN2 Therapeutics, Inc.. 1,108 shares at an average of $6.02, traded Sep 9, 2026, filed Sep 11, 2026.
Score components
- +15RoleDirector
- 0Trade size$7k at market
- 0Share of holdings soldSold 0.2% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-389545, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | SOpen-market sale Common Stockindirect: See footnotes10b5-1 | -523 | $6.02 | $3,151 | 557,467 | 31 d ago |
| Sep 9, 2026 | SOpen-market sale Common Stockindirect: See footnotes10b5-1 | -585 | $6.02 | $3,524 | 624,765 | 31 d ago |
Related signals
Other insiders at AN2 Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | AN2 Therapeutics, Inc. | Robin Shane Readnour director | $97k 16,119 shares | -3% | |
| 23Weak | AN2 Therapeutics, Inc. | Sarah Joanne Williams Principal Accounting Officer | $1,504 272 shares | -0% | |
| 21Weak | ANTXbuy AN2 Therapeutics, Inc. | Margaret M FitzPatrick director | $12k 2,098 shares | +24% | |
| 15Weak | ANTXsell AN2 Therapeutics, Inc. | Sarah Joanne Williams Principal Accounting Officer | $347 327 shares | -0% | |
| 35Weak | AN2 Therapeutics, Inc. | Joshua M Eizen See Remarks | $25k 24,854 shares | -14% | |
| 35Weak | AN2 Therapeutics, Inc. | Sanjay Chanda Chief Development Officer | $9,332 9,251 shares | -11% | |
| 30Weak | AN2 Therapeutics, Inc. | Stephen David Prior Chief Strategy Officer | $6,507 6,462 shares | -10% | |
| 42Moderate | AN2 Therapeutics, Inc. | Lucy Day Chief Financial Officer | $8,883 8,807 shares | -10% | |
| 23Weak | AN2 Therapeutics, Inc. | Stephen David Prior Chief Strategy Officer | $872 765 shares | -1% | |
| 23Weak | AN2 Therapeutics, Inc. | Joshua M Eizen See Remarks | $3,214 2,819 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.